InnovAge Holding (INNV) Could Be 75% Below Fair Value After Profit And 2027 Outlook

Why InnovAge Holding’s latest earnings matter for investors

InnovAge Holding (INNV) just posted fourth quarter results that turned a prior loss into a profit, paired with fresh full year 2027 revenue guidance that sets a clear reference point for expectations.

The healthcare provider to seniors reported fourth quarter sales of US$261.51 million and revenue of US$261.95 million, with net income of US$8.29 million compared with a loss in the same period last year.

Management now projects full fiscal 2027 revenue between US$1.05b and US$1.085b, a range that investors can use as a benchmark when assessing how the business tracks over coming quarters.

At a share price of US$10.92, InnovAge Holding has logged a 2.06% 1 day share price return and an 18.57% 90 day share price return. The 1 year total shareholder return of 135.85% and 3 year total shareholder return of 62.02% point to momentum that earnings and new 2027 guidance appear to have reinforced rather than reset.

Compare InnovAge Holding’s move back into profitability with a curated set of healthcare peers on the 30 resilient stocks with low risk scores, a tool that screens for resilience as well as return potential.

After a 1 year total return above 100% and a swing back to profit, InnovAge Holding now asks a harder question. Does the current price still compensate you for the operational and regulatory risks on the table?

Most Popular Narrative: 9% Overvalued

Compared with the last close at $10.92, the most followed narrative pegs InnovAge Holding’s fair value at $10, suggesting a modest premium that hinges on execution and risk control.

• Enrollment growth is accelerating, supported by strong underlying demand for care models that allow seniors to remain at home, directly benefiting from the expanding 65+ demographic in the U.S. This is expected to support the company’s future revenue trends.

See why 1 investors see InnovAge Holding as 9% overvalued.

Result: Fair Value of $10 (OVERVALUED)

Still, the bullish InnovAge Holding narrative can be challenged if cost growth continues to outrun revenue, or if regulatory and compliance pressures remain elevated.

Find out about the key risks to this InnovAge Holding narrative.

Another view on InnovAge Holding’s valuation

The analyst narrative frames InnovAge Holding as roughly 9% overvalued at $10.92, yet the Simply Wall St DCF model paints a very different picture. On that cash flow view, the shares trade about 74.5% below an estimated value of $42.89, which signals a large implied upside instead of a small premium.

When one framework hints at a mild overpay and another points to a deep discount, the real question is which set of assumptions about margins, growth and risk you find more realistic.

Look into how the SWS DCF model arrives at its fair value.

Next Steps

If this mix of optimism and caution around InnovAge Holding feels familiar, that is the point. You still need to pressure test the numbers yourself and see whether the opportunity fits your risk tolerance by reviewing the 3 key rewards.

Looking for more investment ideas beyond InnovAge Holding?

If InnovAge Holding has sharpened your focus, use that momentum to size up fresh ideas before the next move catches you watching instead of prepared.

• Target potential mispricings by scanning companies that combine solid fundamentals with room for improvement using the 35 high quality undervalued stocks.
• Lock in potential income streams by searching for companies with robust payout profiles through the 7 dividend fortresses.
• Prioritise resilience by reviewing a list of solid balance sheet and fundamentals (23 results) that can help you avoid fragile balance sheets before they become a problem.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com